UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On January 23, 2023, CymaBay Therapeutics, Inc. suspended the use of its prospectus filed with the Securities and Exchange Commission (the “SEC”) and dated July 13, 2020 relating to the Controlled Equity OfferingSM Sales Agreement, dated July 2, 2020 (the “Sales Agreement”), by and between CymaBay and Cantor Fitzgerald & Co. CymaBay will not make any sales of common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the SEC. Other than the termination of the prospectus relating to the Sales Agreement, the Sales Agreement remains in full force and effect.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CymaBay Therapeutics, Inc. | ||
By: | /s/ Paul Quinlan | |
Name: | Paul Quinlan | |
Title: | General Counsel |
Dated: January 23, 2023
Document and Entity Information |
Jan. 23, 2023 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001042074 |
Document Type | 8-K |
Document Period End Date | Jan. 23, 2023 |
Entity Registrant Name | CymaBay Therapeutics, Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-36500 |
Entity Tax Identification Number | 94-3103561 |
Entity Address, Address Line One | 7575 Gateway Blvd. |
Entity Address, Address Line Two | Suite 110 |
Entity Address, City or Town | Newark |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94560 |
City Area Code | (510) |
Local Phone Number | 293-8800 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common stock, $0.0001 par value per share |
Trading Symbol | CBAY |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
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end